Efficacy of Sofosbuvir and Ribavirin in Children Presenting with Hepatitis C at Tertiary Care Hospital, Faisalabad

Authors

  • Nagina Shahzadi
  • Naureen Kanwal Satti
  • Huma Arshad
  • Nadeem Hashmat

DOI:

https://doi.org/10.51985/JBUMDC2021128

Keywords:

Chronic Hepatitis C, Children, Antiviral, Sofosbuvir, Ribavirin

Abstract

Objectives: To assess efficacy, safety, and outcome of combination of Sofosbuvir and Ribavirin in various genotypes, in
children with hepatitis C infection.
Study design and setting: It was a quasi-experimental study, conducted at the Gastroenterology and Hepatology Department,
Children Hospital Faisalabad, from August 2017 to August 2021.
Methodology: 50 confirmed cases of HCV infection aged 5 to 18 years, were given an oral dose of Sofosbuvir and Ribavirin
daily for 12 weeks. PCR was assessed at 4 weeks (for Rapid Viral Response (RVR)) and repeated at 8 weeks and 12 weeks
(for Early Viral Response (EVR)) and again 12 weeks after the completion of therapy for Sustained Viral Response (SVR)).
Primary outcome was the number who achieved an SVR at 12 weeks (SVR12) after completion of treatment with a viral
load below quantitation level.
Results: Genotype 3 was found in 80% , type 1 in 6% , type 2 in 4% and 10% were untypeable. All children were PCR
positive at presentation; 96% became PCR negative at 4 weeks (RVR), while 100 percent were negative at 8 weeks, 12
weeks (EVR), and SVR 12 weeks after completion of 12 week course was 100%.
Conclusion: Although majority of patients were Genotype 3, 12 week course of Sofosbuvir and Ribavirin of hepatitis
C-infected children was highly effective, with 100 percent PCR-negative cases at 8 weeks and 12 weeks with only minor
side effects, and, SVR of 100% twelve weeks after completion of therapy

References

Lombardi A, Mondelli MU; ESCMID Study Group for Viral

Hepatitis (ESGVH). Hepatitis C: Is eradication possible?

Liver Int. 2019;39(3):416-426. Doi; 10.1111/liv. 14011. E

pub 2019 Jan 10. PMFD: 30472772.

Aiman Arshad, Usman Ali Ashfaq. Epidemiology of Hepatitis

infection in Pakistan; current estimate and major risk factors.

Crit Rev EukaryotGene Exp. 2020; 20: 587.

World Health Organisation. Global Health Sector Strategy

on Viral Hepatitis 2016-2021. Geneva Switzerland : World

Health Organisation ; 2016.

Petruzziello A, Marigliano S, Loquercio G, Cozzolino A,

Cacciapuoti C. Global epidemiology of hepatitis C virus

infection: An up-date of the distribution and circulation of

hepatitis C virus genotypes. World J Gastroenterol.

;22(34):7824-40. Doi: 10.3748/wjg.v22. 134.7824.

Haqqi A, Munir R, Khalid M, Khurram M, Zaid M, Ali M,

et. al. Prevalence of Hepatitis C Virus Genotypes in Pakistan:

Current Scenario and Review of Literature. Viral Immunol.

;32(9):402-413. https:// doi.org/10.1089/vim.2019.0058.

Sohail Akhtar, Jamal Abdul Nasir, Andrew Hinde. The

prevalence of Hepatitis C virus infection in Beta thalassemia

patients in Pakistan; a systematic review and meta-analysis.

BMC Public Health. 2020;20:587. https:// doi.org/10-

/s12889-020-8414-5.

Samo AA, Laghari ZA, Baig NM, Khoso GM. Prevalence

and Risk Factors Associated with Hepatitis B and C in

Nawabshah, Sindh, Pakistan. Am J Trop Med Hyg.

;104(3):1101–5. Doi: 10.4269/ajtmh. 20-1228.

Treatment of adolescents and children with chronic HCV

infection. Policy Brief. Geneva. World Health Organisation

Hashmi MA, Cheema HA. Effectiveness and Safety of

Sofosbuvir in Treatment-Näive Children with Hepatitis C

Infection. J Coll Physicians Surg Pak. 2017;27(7):423-426.

Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance

Panel. Hepatitis C Guidance 2019 Update: American

Association for the Study of Liver Diseases-Infectious Diseases

Society of America Recommendations for Testing, Managing,

and Treating Hepatitis C Virus Infection. Hepatology.

;71(2):686-721. https://doi.org/10.1002/hep.31060

Rosenthal, P. Kathleen B Schwartz, Regino P Gonzales-Peralta

et al. Sofosbuvir and Ribavirin therapy for children aged 3

to 12 years with hepatitis C virus genotype 2 or 3 infection.

Hepatology, 2020;71(1): 31-43

Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, Lin CH,

Kelly DA, Nightingale S, et. al. Sofosbuvir and Ribavirin

Therapy for Children Aged 3 to <12 Years With Hepatitis C

Virus Genotype 2 or 3 Infection. Hepatology. 2020;71(1):31-

https://researcherprofiles.org/profile/57844836

Karnsakul W, Schwarz KB. Management of Hepatitis C

Infection in children in the era of Direct-acting Antiviral

Agents. J Viral Hepat. 2019;26(9):1034-1039. doi:

1111/jvh.13113.

Squires JE, Balistreri WF. Hepatitis C virus infection in

children and adolescents. Hepatology communications.

;1(2):87-98. https://doi.org/10.1002/hep4.1028.

Hashmi, MA and Anwar A. Risk Factors for Viral Hepatitis

B and C Infection in Children. PAFMJ, 2018; 68(3): 627-33.

Huang Y, Li MH, Hou M, Xie Y. Peginterferon alfa-2a for

the treatment of chronic hepatitis C in the era of direct-acting

antivirals. Hepatobiliary Pancreat Dis Int. 2017;16(5):470-

Murray KF, Balistreri WF, Bansal S, Whitworth S, Evans

HM and Gonzalez-Peralta RP et. al. Safety and Efficacy of

Ledipasvir–Sofosbuvir With or Without Ribavirin for Chronic

Hepatitis C in Children Ages 6-11. Hepatology.

;68(6):2158-66. Doi: 10.1002/hep.30123.

Schwarz KB, Rosenthal P, Murray KF, Honegger JR, Hardikar

W, Hague R, Mittal N, Massetto B, Brainard DM, Hsueh CH,

Shao J. Ledipasvir-sofosbuvir for 12 weeks in children 3 to<

years old with chronic hepatitis C. Hepatology.

;71(2):422-30. Doi: 10.1002/hep.30830.

El-Araby HA, Behairy BE, El-Guindi MA, Adawy NM, Allam

AA, Sira AM, et. al. Generic sofosbuvir/ledipasvir for the

treatment of genotype 4 chronic hepatitis C in Egyptian

children (9-12 years) and adolescents. Hepatol Int.

;13(6):706-714. Doi: 10.1007/s12072-019-09985-w.

Alkaaby BA, Al-Ethawi AE. The effectiveness of oral antiviral

(Sofosbuvir/Ledipasvir) in treating children with HCV

infection. Pak J Med Sci. 2018;34(6):1353-1356. Doi:

12669/pjms.346.15722.

Downloads

Published

2023-04-03

How to Cite

Shahzadi , N. ., Satti, N. K. ., Arshad, H. ., & Hashmat, N. . (2023). Efficacy of Sofosbuvir and Ribavirin in Children Presenting with Hepatitis C at Tertiary Care Hospital, Faisalabad. Journal of Bahria University Medical and Dental College, 13(02), 82–86. https://doi.org/10.51985/JBUMDC2021128

Issue

Section

Original Articles

Most read articles by the same author(s)